CareDx (CDNA) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
CareDx Reports First Quarter 2022 Results
May 5, 2022 4:01 PM EDTSOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today reported financial results for the first quarter ended March 31, 2022.
Recent Highlights:
Achieved total revenue of $79.4 million for the three months ended March 31, 2022, increasing 18% year-over-yearProvided approximately 42,600 AlloSure and AlloMap patient results in the quarter, with March being our highest ever month of testing volume for Heart and Kidney Testing... MoreCareDx Reports First Quarter 2022 Results
May 5, 2022 4:01 PM EDTSOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today reported financial results for the first quarter ended March 31, 2022.
Recent Highlights:
Achieved total revenue of $79.4 million for the three months ended March 31, 2022, increasing 18% year-over-yearProvided approximately 42,600 AlloSure and AlloMap patient results in the quarter, with March being our highest ever month of testing volume for Heart and Kidney... More